tiprankstipranks
TransMedics price target lowered to $110 from $180 at Piper Sandler
The Fly

TransMedics price target lowered to $110 from $180 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on TransMedics (TMDX) to $110 from $180 and keeps an Overweight rating on the shares. A debate on heart transplant versus mechanical circulatory support called for expansion of the donor pool through adopting DCD procurement and preservation technologies. The firm believes the total market opportunity is likely underestimated as limited donor availability was noted as a reason why patients don’t even make it on the waitlist. Market expansion would primarily benefit TransMedics considering it has the only FDA approved machine perfusion device for hearts at the moment, Piper adds.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App